SGLT2 inhibitors may offer benefit beyond diabetes

Amy Kang^{1

2}, Meg J Jardine^{3

4

5}

Affiliations

¹ Renal and Metabolic Division, The George Institute for Global Health, UNSW Sydney, Sydney, Australia.
² Prince of Wales Hospital, Sydney, Australia.
³ Renal and Metabolic Division, The George Institute for Global Health, UNSW Sydney, Sydney, Australia. MegJ@ctc.usyd.edu.au.
⁴ NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia. MegJ@ctc.usyd.edu.au.
⁵ Concord Repatriation General Hospital, Sydney, Australia. MegJ@ctc.usyd.edu.au.

Review

Amy Kang et al. Nat Rev Nephrol. 2021 Feb.

. 2021 Feb;17(2):83-84.

doi: 10.1038/s41581-020-00391-2.

Amy Kang^{1

2}, Meg J Jardine^{3

4

5}

¹ Renal and Metabolic Division, The George Institute for Global Health, UNSW Sydney, Sydney, Australia.
² Prince of Wales Hospital, Sydney, Australia.
³ Renal and Metabolic Division, The George Institute for Global Health, UNSW Sydney, Sydney, Australia. MegJ@ctc.usyd.edu.au.
⁴ NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia. MegJ@ctc.usyd.edu.au.
⁵ Concord Repatriation General Hospital, Sydney, Australia. MegJ@ctc.usyd.edu.au.

No abstract available

References

1. McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995–2008 (2019). - DOI
1. Petrie, M. C. et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA 323, 1353–1368 (2020). - DOI
1. Jhund, P. S. et al. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation https://doi.org/10.1161/CIRCULATIONAHA.120.050391 (2020). - DOI - PubMed - PMC
1. Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019). - DOI
1. Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413–1424 (2020). - DOI